Daiichi Sankyo's Edoxaban Enters Its First Market; Eisai "Very Pleased" With Eribulin Japanese Price Listing
This article was originally published in PharmAsia News
TOKYO - Drugmakers introduced a number of new products in Japan this week, including the first launch globally of Daiichi Sankyo Co. Ltd.'s oral factor Xa inhibitor edoxaban, following the release of National Health Insurance price listings
You may also be interested in...
Kyowa Hakko Kirin's Poteligeo cleared for first global market launch, earning a 10% premium for added-value benefits.
Japan’s Chuikyo is reviewing HTA systems in the UK, Germany, Australia and South Korea, but is also considering its own variation to reward industry compliance.